Recent news highlights Vaxart’s financial performance, clinical development progress, and corporate activities including stockholder meetings and licensing agreements.

• Vaxart reported a Q2 loss but showed revenue growth, with revenue jumping 520% in fiscal Q2 2025, reflecting increased government contract activity and collaborations [N5][N6].
• The company announced results from its 2025 Annual Meeting of Stockholders and updates on clinical trial data releases, including Norovirus Phase I trial topline data [N5].
• Vaxart entered into a licensing and collaboration agreement with Dynavax for its oral COVID-19 vaccine candidate, receiving upfront payments totaling approximately $30 million [S2].
• Stockholder proposals and corporate governance matters, including a reverse stock split proposal, were communicated to shareholders in mid-2025 [N5].
• Vaxart’s stock experienced notable trading activity, including a 30% increase on a day in June 2025, reflecting market interest [N5].
• The company’s revenue and loss reports have been covered in multiple news articles, indicating ongoing investor and analyst attention [N5][N6].

Vaxart’s proprietary oral vaccine platform offers a novel approach to immunization, potentially improving patient compliance and distribution logistics. The company’s significant government contracts and collaborations, including the licensing deal with Dynavax, provide financial resources and validation of its technology. Recent revenue growth and improved net income demonstrate operational progress. The experienced management team with deep biotech industry expertise supports strategic execution. Continued clinical development and successful commercialization of oral vaccines could enhance the company’s market position and revenue streams.

Vaxart remains a clinical-stage company with no approved products, exposing it to risks inherent in drug development including clinical trial failures and regulatory hurdles. The company’s reliance on government contracts and collaborations for funding introduces dependency risks. Operating losses and accumulated deficits highlight ongoing financial challenges. Liquidity, while moderate, may require additional capital raises, which could dilute existing shareholders. Market acceptance of oral vaccines and competition from established injectable vaccines present commercial risks. The company’s stock trades on the OTCQX market, which may limit liquidity and investor access.

Vaxart’s moat is based on its proprietary oral recombinant protein vaccine platform, which differentiates it from traditional injectable vaccines. The company’s collaborations and licensing agreements, such as with Dynavax, provide access to development and commercialization resources. Government contracts, including those from HHS BARDA, offer a stable funding source supporting clinical development. The company’s specialized focus on oral vaccines for infectious diseases, including COVID-19 and Norovirus, positions it in a niche market with potential barriers to entry due to technological complexity and regulatory requirements.

• Clinical and Regulatory Risk: As a clinical-stage biotech company, Vaxart faces risks related to the success of its clinical trials and obtaining regulatory approvals for its vaccine candidates.
• Funding and Liquidity Risk: The company depends on government contracts, collaborations, and equity financing to fund operations. Insufficient funding or inability to raise capital could impact its ability to continue development.
• Market Acceptance Risk: The commercial success of Vaxart’s oral vaccines depends on market acceptance, which may be affected by competition from traditional injectable vaccines and other novel platforms.
• Operational Risk: Execution risks include managing clinical programs, collaborations, and scaling operations effectively to achieve milestones and commercial objectives.

• Vaxart, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
• The company operates in one reportable segment and is headquartered in South San Francisco, California.
• Vaxart's primary source of financing includes sale and issuance of common stock and funding from the Biomedical Advanced Research and Development Authority (HHS BARDA), a division of the U.S. Department of Health and Human Services.
• In 2025, Vaxart entered into an Exclusive License and Collaboration Agreement and a Securities Purchase Agreement with Dynavax Technologies Corporation, granting Dynavax an exclusive worldwide license to develop and commercialize Vaxart's oral COVID-19 vaccine candidate, receiving approximately $30 million in upfront fees and stock purchase.
• The company had cash, cash equivalents, and short-term investments totaling approximately $28.8 million as of September 30, 2025.
• As of December 31, 2025, Vaxart reported total revenue of $237.3 million and net income of $16.3 million, with basic and diluted EPS of $0.07.
• The company’s liquidity ratios as of December 31, 2025, include a current ratio of 1.57 and a cash ratio of 0.47, indicating moderate liquidity.
• Vaxart's revenue includes government contract revenue, notably from HHS BARDA, with $133 million recognized in the first nine months of 2025, reflecting significant contract activity.
• Research and development expenses were $156.4 million for the nine months ended September 30, 2025, reflecting substantial investment in clinical programs, including COVID-19 and Norovirus vaccine candidates.
• The company has a history of stock issuances including an underwritten offering in June 2024 raising $37.5 million net proceeds and at-the-market offerings in 2025.
• Management team includes Steven Lo as CEO since March 2024, with extensive biotech industry experience; Jeroen Grasman as CFO since May 2025; and Sean Tucker, Ph.D., as Chief Scientific Officer.
• The company’s royalty revenue relates to a collaboration and license agreement with Daiichi Sankyo for the sale of Inavir in Japan, with royalties expected to cease after patent expiration in August 2036.
• Vaxart’s stockholders’ equity was $26.8 million as of September 30, 2025, down from $58.9 million at the end of 2024, reflecting accumulated deficit and operating results.
• The company’s total liabilities increased to $182.2 million as of September 30, 2025, including significant deferred government revenue and accounts payable.
• Vaxart’s net loss for the nine months ended September 30, 2025 was $38.7 million, an improvement compared to prior periods.
• The company’s business model relies heavily on government contracts and collaborations for funding and development of its vaccine candidates.
• Vaxart’s oral vaccine platform targets infectious diseases including COVID-19 and Norovirus, with ongoing clinical trials and development programs.
• The company’s financial statements are prepared under U.S. GAAP and assume the company will continue as a going concern, supported by recent capital raises and collaborations.
• Vaxart’s stock trades on the OTCQX Best Market under the symbol VXRT.
• The company’s recent news includes reports of Q2 losses with revenue growth, significant revenue jumps in fiscal Q2, and announcements related to clinical trial data releases and stockholder meetings.